[{"id":"6a0cd4a1-906c-4468-b9bf-fae916dc7b2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05287451","created_at":"2022-03-18T11:54:35.018Z","updated_at":"2024-07-02T16:34:26.864Z","phase":"","brief_title":"Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study","source_id_and_acronym":"NCT05287451","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • BRIP1 • RAD51C • RAD51D","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • BRIP1 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/10/2022","start_date":" 05/10/2022","primary_txt":" Primary completion: 12/26/2026","primary_completion_date":" 12/26/2026","study_txt":" Completion: 12/26/2026","study_completion_date":" 12/26/2026","last_update_posted":"2024-06-12"},{"id":"62aca2f8-43be-49bc-a240-562947c24958","acronym":"D5330C00004","url":"https://clinicaltrials.gov/study/NCT02264678","created_at":"2021-01-17T17:33:57.498Z","updated_at":"2024-07-02T16:35:02.492Z","phase":"Phase 1/2","brief_title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","source_id_and_acronym":"NCT02264678 - D5330C00004","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ATM • HRD • BRCA • RAD51C • RAD51D","pipe":" | ","alterations":" HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation • RAD51 mutation","tags":["HER-2 • ATM • HRD • BRCA • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • ceralasertib (AZD6738) • saruparib (AZD5305)"],"overall_status":"Recruiting","enrollment":" Enrollment 466","initiation":"Initiation: 10/31/2014","start_date":" 10/31/2014","primary_txt":" Primary completion: 08/05/2026","primary_completion_date":" 08/05/2026","study_txt":" Completion: 08/05/2026","study_completion_date":" 08/05/2026","last_update_posted":"2024-05-21"},{"id":"b82d5afc-83e5-4037-9280-7d0e4dfd7f17","acronym":"NCI10217","url":"https://clinicaltrials.gov/study/NCT03842228","created_at":"2021-01-18T18:58:03.649Z","updated_at":"2024-07-02T16:35:02.758Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations","source_id_and_acronym":"NCT03842228 - NCI10217","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation","tags":["PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 11/21/2019","start_date":" 11/21/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-17"},{"id":"b5a0dd9e-84d2-4dd2-8ee2-be7c6322c1b0","acronym":"TUBA-WISP II","url":"https://clinicaltrials.gov/study/NCT04294927","created_at":"2021-01-18T20:50:21.878Z","updated_at":"2024-07-02T16:35:09.512Z","phase":"","brief_title":"TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention","source_id_and_acronym":"NCT04294927 - TUBA-WISP II","lead_sponsor":"University Medical Center Nijmegen","biomarkers":" BRCA1 • BRCA2 • BRIP1 • RAD51C • RAD51D","pipe":" | ","alterations":" BRIP1 mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • BRIP1 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRIP1 mutation • RAD51 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 3000","initiation":"Initiation: 03/01/2020","start_date":" 03/01/2020","primary_txt":" Primary completion: 02/17/2040","primary_completion_date":" 02/17/2040","study_txt":" Completion: 02/17/2040","study_completion_date":" 02/17/2040","last_update_posted":"2024-04-16"},{"id":"731ab927-ac32-42ee-9011-baa1124b987d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05229588","created_at":"2022-02-12T17:48:13.004Z","updated_at":"2024-07-02T16:35:21.201Z","phase":"Phase 2","brief_title":"Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations","source_id_and_acronym":"NCT05229588","lead_sponsor":"HonorHealth Research Institute","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-02-02"},{"id":"be84ddd3-f2ce-46d3-ae9d-39c0fd0d285e","acronym":"DIDO","url":"https://clinicaltrials.gov/study/NCT04983745","created_at":"2021-07-30T17:55:02.511Z","updated_at":"2024-07-02T16:35:25.580Z","phase":"Phase 2","brief_title":"Niraparib and Dostarlimab in HRD Solid Tumors","source_id_and_acronym":"NCT04983745 - DIDO","lead_sponsor":"West Cancer Center","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI","pipe":" | ","alterations":" BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-12-21"},{"id":"e7603ed6-5e6f-419a-8bfc-ae608e45f0bf","acronym":"BRACeD","url":"https://clinicaltrials.gov/study/NCT04038502","created_at":"2021-01-18T19:48:50.249Z","updated_at":"2024-07-02T16:35:30.850Z","phase":"Phase 2","brief_title":"Carboplatin or Olaparib for BRcA Deficient Prostate Cancer","source_id_and_acronym":"NCT04038502 - BRACeD","lead_sponsor":"VA Office of Research and Development","biomarkers":" RAD51B • RAD51C • RAD51D • RAD54L","pipe":" | ","alterations":" ATRX mutation • RAD54L mutation • RAD51 mutation","tags":["RAD51B • RAD51C • RAD51D • RAD54L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • RAD54L mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 08/29/2025","study_completion_date":" 08/29/2025","last_update_posted":"2023-11-01"},{"id":"ff7c1831-8767-420c-a63e-fc4a8e3a8271","acronym":"","url":"https://clinicaltrials.gov/study/NCT04042831","created_at":"2021-01-18T19:49:54.652Z","updated_at":"2024-07-02T16:35:33.579Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","source_id_and_acronym":"NCT04042831","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • BRCA • CHEK2 • RAD51 • ATR • BRIP1 • NBN • EMSY","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • BRCA • CHEK2 • RAD51 • ATR • BRIP1 • NBN • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/24/2020","start_date":" 06/24/2020","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2023-10-13"},{"id":"651ef873-d60d-4a2e-8a95-19b5f633efb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02511223","created_at":"2021-01-18T12:07:41.039Z","updated_at":"2024-07-02T16:35:50.078Z","phase":"Phase 2","brief_title":"Efficacy and Safety of PARPi to Treat Pancreatic Cancer","source_id_and_acronym":"NCT02511223","lead_sponsor":"Sheba Medical Center","biomarkers":" BRCA • RAD51","pipe":" | ","alterations":" BRCA mutation • RAD51 mutation","tags":["BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 04/18/2021","primary_completion_date":" 04/18/2021","study_txt":" Completion: 04/18/2021","study_completion_date":" 04/18/2021","last_update_posted":"2023-04-19"},{"id":"c32a9424-3409-40c6-a992-e2f21929c6bf","acronym":"RADIOLA","url":"https://clinicaltrials.gov/study/NCT05340413","created_at":"2022-04-22T14:53:48.015Z","updated_at":"2024-07-02T16:35:50.312Z","phase":"Phase 2","brief_title":"Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.","source_id_and_acronym":"NCT05340413 - RADIOLA","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • HRD • PALB2 • RAD51 • RAD51C • RAD51D","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • PALB2 mutation • ER positive + PGR positive • PGR positive • RAD51C mutation • RAD51D mutation • PGR negative • RAD51 mutation","tags":["HER-2 • PGR • BRCA1 • BRCA2 • HRD • PALB2 • RAD51 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • PALB2 mutation • ER positive + PGR positive • PGR positive • RAD51C mutation • RAD51D mutation • PGR negative • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-04-18"},{"id":"b2d3e38f-bf00-4920-aff3-f61daeca6754","acronym":"","url":"https://clinicaltrials.gov/study/NCT02873975","created_at":"2021-01-18T14:06:40.199Z","updated_at":"2024-07-02T16:36:02.020Z","phase":"Phase 2","brief_title":"A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency","source_id_and_acronym":"NCT02873975","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • MYC amplification • PALB2 mutation • CCNE1 amplification • FBXW7 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • MYC amplification • PALB2 mutation • CCNE1 amplification • FBXW7 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 10/12/2016","start_date":" 10/12/2016","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2022-10-21"},{"id":"051f2842-0405-4b42-862d-b02385ea0671","acronym":"FAB","url":"https://clinicaltrials.gov/study/NCT04780945","created_at":"2021-03-04T13:52:39.615Z","updated_at":"2024-07-02T16:36:32.538Z","phase":"Phase 2","brief_title":"Functional Analysis of BRCAness","source_id_and_acronym":"NCT04780945 - FAB","lead_sponsor":"Leiden University Medical Center","biomarkers":" BRCA1 • BRCA • RAD51","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • RAD51 mutation","tags":["BRCA1 • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 01/21/2019","start_date":" 01/21/2019","primary_txt":" Primary completion: 12/21/2022","primary_completion_date":" 12/21/2022","study_txt":" Completion: 06/21/2023","study_completion_date":" 06/21/2023","last_update_posted":"2021-04-01"},{"id":"6620b65a-3bbd-43be-bc87-a299b4dfa310","acronym":"","url":"https://clinicaltrials.gov/study/NCT04764084","created_at":"2021-02-21T12:52:13.701Z","updated_at":"2024-07-02T16:36:34.306Z","phase":"Phase 1","brief_title":"Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors","source_id_and_acronym":"NCT04764084","lead_sponsor":"Beijing Cancer Hospital","biomarkers":" HER-2 • BRCA1 • BRCA2 • HRD • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1","pipe":" | ","alterations":" BRCA1 mutation • HER-2 negative • ATM mutation • PALB2 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD51 mutation","tags":["HER-2 • BRCA1 • BRCA2 • HRD • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HER-2 negative • ATM mutation • PALB2 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 11/01/2021","primary_completion_date":" 11/01/2021","study_txt":" Completion: 02/28/2023","study_completion_date":" 02/28/2023","last_update_posted":"2021-02-22"},{"id":"555454ba-141a-407e-8e64-d23c36651dd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03432676","created_at":"2021-01-18T16:55:55.122Z","updated_at":"2024-07-02T16:36:59.192Z","phase":"Phase 2","brief_title":"Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer","source_id_and_acronym":"NCT03432676","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • ATM • BRCA • RAD51","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • BRCA mutation • RAD51 mutation","tags":["BRCA1 • ATM • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • BRCA mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • epacadostat (INCB024360)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/31/2019","start_date":" 07/31/2019","primary_txt":" Primary completion: 04/30/2020","primary_completion_date":" 04/30/2020","study_txt":" Completion: 04/30/2021","study_completion_date":" 04/30/2021","last_update_posted":"2019-05-30"}]